Skye Bioscience and Redx Pharma Announce Transaction Agreement and $125 Million in Financings
Skye Bioscience announced a definitive agreement to acquire Redx Pharma, creating a combined fibrosis-focused biotech company named Fibrx Therapeutics. The new entity, led by Redx's management, will trade on Nasdaq and be funded with approximately $125 million in new financing to support clinical development of novel anti-fibrotic therapies, includ…